Endo-MT may contribute to both intrinsic and acquired tumor resistance to anti-VEGF therapy, by VEGFR-2 downregulation-mediated treatment unresponsiveness and by selective regrowth of highly proliferative, transformed ECs after treatment, respectively. Here, KDR is linked to neoplasm.